Patents by Inventor Richard D. DiMarchi

Richard D. DiMarchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon analogs exhibiting GIP receptor activity
    Patent number: 9340600
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: May 17, 2016
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventor: Richard D. DiMarchi
  • Glucagon Analogs Exhibiting GIP Receptor Activity
    Publication number: 20160115215
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 28, 2016
    Inventors: Richard D. Dimarchi, Brian P. Ward
  • Glucagon/GLP-1 receptor co-agonists
    Patent number: 9309301
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: April 12, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley, Bin S. Yang
  • PRODRUGS WITH PROLONGED ACTION
    Publication number: 20160058881
    Abstract: A prodrug derivative of a bioactive peptide (or polypeptide) is provided that exhibits prolonged half-life in serum and prolonged action in vivo, compared to the parent peptide or polypeptide. In some embodiments, the peptide is selected from the group consisting of glucagon, exendin-4, GLP-1, GLP-2, GIP, vasoactive intestinal peptide (VIP), Pituitary adenylate cyclase-activating polypeptide 27 (PACAP-27), peptide histidine methionine (PHM), oxyntomodulin, secretin, osteocalcin, growth hormone releasing hormone, as well as analogs, derivatives and conjugates.
    Type: Application
    Filed: March 14, 2014
    Publication date: March 3, 2016
    Inventors: RICHARD D. DIMARCHI, Binbin KOU
  • GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY
    Publication number: 20160051688
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Application
    Filed: August 28, 2015
    Publication date: February 25, 2016
    Inventors: Richard D. DiMARCHI, Lianshan ZHANG
  • GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS
    Publication number: 20160052989
    Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-1 and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
    Type: Application
    Filed: August 31, 2015
    Publication date: February 25, 2016
    Inventors: Richard D. DiMARCHI, Tao MA
  • Modified human four helical bundle polypeptides and their uses
    Patent number: 9260472
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: February 16, 2016
    Assignee: AMBRX, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. Dimarchi, Anna-Maria A. Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Glucagon analogs exhibiting GIP receptor activity
    Patent number: 9249206
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: February 2, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Brian P. Ward
  • INSULIN-INCRETIN CONJUGATES
    Publication number: 20160024169
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the insulin/incretin conjugate has agonist activity at both the insulin receptor and the corresponding incretin receptor. Insulin is a proven therapy for the treatment of juvenile-onset diabetes and later-stage adult-onset diabetes. The peptide is biosynthesized as a larger linear precursor of low potency (approximately 2% to 9% of native insulin), named proinsulin. Proinsulin is proteolytically converted to insulin by the selective removal of a 35-residue connecting peptide (C peptide).
    Type: Application
    Filed: March 5, 2014
    Publication date: January 28, 2016
    Inventors: RICHARD D. DIMARCHI, TODD PARODY, JIE HAN, PENGYUN LI
  • GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
    Publication number: 20150376256
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 31, 2015
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • O-GLYCOSYLATED CARBOXY TERMINAL PORTION (CTP) PEPTIDE-BASED INSULIN AND INSULIN ANALOGUES
    Publication number: 20150374795
    Abstract: Compositions and formulations comprising insulin or insulin analogues comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-188 to 142 of the beta subunit of human chorionic gonadotropin (hCG?) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analogue is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogues are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogues comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans.
    Type: Application
    Filed: November 22, 2013
    Publication date: December 31, 2015
    Applicants: MERCK SHARP & DOHME CORP., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. DiMarchi, Pengyun Li, Michael Meehl
  • ANALOGS OF GLUCAGON EXHIBITING GIP RECEPTOR ACTIVITY
    Publication number: 20150368310
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 24, 2015
    Inventors: Richard D. Dimarchi, David L. Smiley, Konrad H. Bleicher, Eric A. Kitas
  • Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity
    Publication number: 20150320871
    Abstract: Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Application
    Filed: July 24, 2015
    Publication date: November 12, 2015
    Inventors: Richard D. DiMARCHI, Bin YANG, Brian FINAN
  • GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
    Publication number: 20150322130
    Abstract: Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-1 activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
    Type: Application
    Filed: May 18, 2015
    Publication date: November 12, 2015
    Inventors: Richard D. DiMARCHI, Tao MA
  • CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES
    Publication number: 20150299285
    Abstract: Insulin analogs comprising a non-native glycosylation site sequence are provided having high potency and specificity for the insulin receptor. In one embodiment a peptide sequence of greater than 18 amino acids is used as a linking moiety to link human insulin A and B chains, or analogs or derivatives thereof, to provide high potency single chain insulin analogs. In one embodiment the linking moiety comprises one or more glycosylation sites. Also disclosed are prodrug and conjugate derivatives of the insulin analogs.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 22, 2015
    Applicant: Indiana University Research And Technology Corporation
    Inventors: Richard D. DIMARCHI, Pengyun LI
  • Glucagon/GLP-1 receptor co-agonists
    Patent number: 9156902
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: October 13, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • GIP receptor-active glucagon compounds
    Patent number: 9150632
    Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 6, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Tao Ma
  • INSULIN ANALOG DIMERS
    Publication number: 20150274802
    Abstract: Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the first and second insulin polypeptide are independently a two chain insulin analog or a single chain analog and the first and second insulin polypeptides are linked to one another via a B29-B29?, B1-C8, B1-B1 or C8-C8 linkage.
    Type: Application
    Filed: September 25, 2013
    Publication date: October 1, 2015
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Yan Zhao
  • Glucagon superfamily peptides exhbiting G protein coupled receptor activity
    Patent number: 9145451
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: September 29, 2015
    Assignees: Indiana University Research and Technology Corporation, Marcadia Biotech, Inc.
    Inventors: Richard D. DiMarchi, Lianshan Zhang
  • Glucagon Analogs Exhibiting GIP Receptor Activity
    Publication number: 20150259393
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: March 23, 2015
    Publication date: September 17, 2015
    Inventors: Richard D. DiMARCHI, Brian P. WARD